Exploring the kynurenine pathway in mild traumatic brain injury: A longitudinal study
Koen Visser,Diana Ciubotariu,Myrthe E. de Koning,Bram Jacobs,Martijn van Faassen,Claude van der Ley,Andrew R. Mayer,Timothy B. Meier,Arno R. Bourgonje,Ido P. Kema,Harry van Goor,Joukje van der Naalt,Harm J. van der Horn
DOI: https://doi.org/10.1111/jnc.16137
2024-05-23
Journal of Neurochemistry
Abstract:(Neuro)inflammation in response to mild traumatic brain injury (mTBI) may lead to the degradation of tryptophan into metabolites of the kynurenine pathway. In this study, we provide evidence for decreases of tryptophan relative to healthy controls in the acute and subacute phase of mTBI. Acute tryptophan concentrations were related to recovery at six‐months post‐mTBI. Furthermore, we found evidence for decreased levels of the kynurenines xanthurenic and picolinic acid that are implicated in the glutamate system. We propose that tryptophan and metabolites or enzymes of the kynurenine pathway may form novel targets for therapeutic supplementation or modulation in mTBI. A potential source of novel biomarkers for mTBI is the kynurenine pathway (KP), a metabolic pathway of tryptophan (Trp), that is up‐regulated by neuroinflammation and stress. Considering that metabolites of the KP (kynurenines) are implicated in various neuropsychiatric diseases, exploration of this pathway could potentially bridge the gap between physiological and psychological factors in the recovery process after mTBI. This study, therefore, set out to characterize the KP after mTBI and to examine associations with long‐term outcome. Patients were prospectively recruited at the emergency department (ED), and blood samples were obtained in the acute phase (<24 h; N = 256) and at 1‐month follow‐up (N = 146). A comparison group of healthy controls (HC; N = 32) was studied at both timepoints. Trp, kynurenines, and interleukin (IL)‐6 and IL‐10 were quantified in plasma. Clinical outcome was measured at six months post‐injury. Trp, xanthurenic acid (XA), and picolinic acid (PA) were significantly reduced in patients with mTBI relative to HC, corrected for age and sex. For Trp (d = −0.57 vs. d = −0.29) and XA (d = −0.98 vs. d = −0.32), larger effects sizes were observed during the acute phase compared to one‐month follow‐up, while for PA (d = −0.49 vs. d = −0.52) effect sizes remained consistent. Findings for other kynurenines (e.g., kynurenine, kynurenic acid, and quinolinic acid) were non‐significant after correction for multiple testing. Within the mTBI group, lower acute Trp levels were significantly related to incomplete functional recovery and higher depression scores at 6 months post‐injury. No significant relationships were found for Trp, XA, and PA with IL‐6 or IL‐10 concentrations. In conclusion, our findings indicate that perturbations of the plasma KP in the hyperacute phase of mTBI and 1 month later are limited to the precursor Trp, and glutamate system modulating kynurenines XA and PA. Correlations between acute reductions of Trp and unfavorable outcomes may suggest a potential substrate for pharmacological intervention.
biochemistry & molecular biology,neurosciences